Quarterly report pursuant to Section 13 or 15(d)

Unaudited Condensed Consolidated Statements of Operations

v3.22.4
Unaudited Condensed Consolidated Statements of Operations - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended 6 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2022
Dec. 31, 2021
Operating expenses:        
Research and development $ 10,945 $ 9,452 $ 18,649 $ 15,226
General and administrative 3,447 2,697 5,961 4,563
Total operating expenses 14,392 12,149 24,610 19,789
Operating loss (14,392) (12,149) (24,610) (19,789)
Non-operating income (expense):        
Interest and other income 849 13 1,249 13
Gain (loss) from change in fair value of derivative liabilities (13) (12) (26) 4
Employee retention credit       231
Interest expense   (445)   (888)
Total non-operating income (expense), net 836 (444) 1,223 (640)
Net loss $ (13,556) $ (12,593) $ (23,387) $ (20,429)
Net loss per common share - basic (in dollars per share) $ (0.26) $ (0.80) $ (0.46) $ (1.69)
Net loss per common share - diluted (in dollars per share) $ (0.26) $ (0.80) $ (0.46) $ (1.69)
Weighted average number of common shares outstanding - basic (in shares) 51,410 15,680 50,969 12,097
Weighted average number of common shares outstanding - diluted (in shares) 51,410 15,680 50,969 12,097